Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test
Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test · Investor's Business Daily

In This Article:

Shares of Bristol Myers Squibb tumbled Wednesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.